Related Experiment Video
Updated: Jul 2, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort
Steven K Hildemann1, Christian Barho, Barbara Karmann
1essex pharma, Medical Department, Munich, Germany. steven.hildemann@essex.de
Insights
Long-term simvastatin/ezetimibe combination therapy effectively lowers lipids and is well-tolerated in cardiovascular risk patients. Patients continuing this lipid-lowering treatment achieved better results than those switching therapies.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Cardiovascular disease necessitates long-term lipid-lowering therapy, often involving drug combinations.
- Simvastatin (SIM) and ezetimibe (EZ) oral combination is a key therapeutic option.
Purpose of the Study:
- To describe usage patterns, effectiveness, and tolerability of long-term SIM/EZ combination therapy.
- To compare SIM/EZ outcomes against other lipid-lowering treatments.
Main Methods:
- Prospective observational study across 512 German general practices.
- 5485 high cardiovascular risk patients were monitored for 1 year on SIM/EZ therapy.
- Data collected on lipid parameters, adverse drug reactions (ADRs), and adverse events.
Main Results:
- 78.6% of patients remained on SIM/EZ combination therapy at 1-year follow-up.
- SIM/EZ significantly reduced LDL-C, total cholesterol, and triglycerides, while increasing HDL-C compared to other therapies.
- 56.6% of patients on SIM/EZ achieved LDL-C targets versus 35.9% on other therapies.
- Adverse drug reactions were rare (0.3%) and non-serious.
Conclusions:
- Long-term SIM/EZ combination therapy demonstrates sustained efficacy and good tolerability for lipid management.
- Patients maintaining SIM/EZ therapy showed superior lipid status improvements compared to those discontinuing or switching treatment.
- Adherence to nutrition counseling correlated with better lipid control in the long term.
Background:
In order to reduce individual cardiovascular risk, many patients require life-long lipid-lowering therapy, often as a drug combination approach. We aimed to describe the usage pattern, effectiveness and tolerability of long-term treatment with lipid-lowering agents, with particular focus on an oral combination of simvastatin (SIM 10, 20, 40 or 80 mg) plus ezetimibe (EZ 10 mg).
Methods:
A prospective, observational study in 512 general practices throughout Germany. From a sample of patients at moderate or high cardiovascular risk who had previously taken part in a half-year study of an SIM/EZ combination, 5485 patients were documented after 1 year of treatment (mean 58 +/- 16 weeks) with regard to lipid parameters, adverse drug reactions (ADRs) and adverse events.
Results:
At the start of follow-up, 78.6% of patients were still on the SIM/EZ combination. At the end of follow-up, mean low density lipoprotein cholesterol (LDL-C) in patients on the combination versus those on other lipid-lowering therapy was reduced by 29.3 vs. 17.6% compared with baseline, total cholesterol by 23.1 vs. 14.5%, mean high density lipoprotein cholesterol (HDL-C) was increased by 15.9 vs. 13.4%, and mean triglycerides were reduced by 16.1 vs. 7.9%. Individual LDL-C targets were achieved by 56.6% on the SIM/EZ combination versus 35.9% on other therapy. In the long term (but not the short term), low acceptance of nutrition counselling as rated by the physician was associated with poor lipid levels. ADRs during follow-up occurred in 18 patients (0.3%; all cases non-serious), with seven cases of myalgia, and three cases each of nausea or arthralgia.
Conclusions:
This observational study showed that long-term therapy with the SIM/EZ combination resulted in sustained beneficial effects on serum lipids and was well-tolerated. Compared to patients with therapy discontinuations or switches, those remaining on the combination had better outcomes regarding lipid status.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:29Therapeutic Drug Monitoring: Affecting Factors